Crohn's Disease and Colitis Trial, Recruiting NCT06311123 Sponsor: University of California, San Diego Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT06311123
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older, of any gender
  • People who were diagnosed with ulcerative colitis (a type of bowel disease) at least 3 months before the screening visit, with the diagnosis confirmed by camera examination of the bowel and tissue samples
  • People whose ulcerative colitis is currently active, as confirmed by a camera examination of the bowel
  • People who are able to sign a written consent form to contribute to a bowel disease sample collection at UC San Diego
  • People who meet the above criteria and whose doctor is considering treatment with a medication called ozanimod, and who will not be receiving biologic medications at the same time

Who may not be able to join:

  • People whose doctor believes they are likely to need surgery to remove part or all of the colon or bowel within 12 weeks of the start of the trial
  • People who currently show signs of a severe bowel flare, a dangerously enlarged colon, or a hole in the bowel wall
  • People who have previously had their entire colon surgically removed
  • People with a low platelet count (the blood cells that help with clotting) below a certain level
  • People who have a current bowel infection caused by bacteria, parasites, or a germ called Clostridioides difficile at the time of screening — though if C. difficile is found, treatment may be given and testing repeated (confirm with trial site)
  • People who are in prison or are being held involuntarily

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8585345495

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 October 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

difference in leukocyte subsets

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov